Index
RUT
P/E
-
EPS (ttm)
-1.13
Insider Own
6.35%
Shs Outstand
43.02M
Perf Week
-2.61%
Market Cap
2.73B
Forward P/E
20.93
EPS next Y
3.03
Insider Trans
-5.83%
Shs Float
40.29M
Perf Month
0.00%
Enterprise Value
2.43B
PEG
-
EPS next Q
-0.22
Inst Own
104.45%
Perf Quarter
-4.70%
Income
-48.27M
P/S
5.10
EPS this Y
61.08%
Inst Trans
-3.55%
Perf Half Y
-17.53%
Sales
535.08M
P/B
7.83
EPS next Y
590.26%
ROA
-8.92%
Perf YTD
-22.47%
Book/sh
8.11
P/C
7.03
EPS next 5Y
-
ROE
-13.96%
52W High
85.25 -25.54%
Perf Year
46.98%
Cash/sh
9.04
P/FCF
-
EPS past 3/5Y
14.26% -3.80%
ROIC
-11.03%
52W Low
38.51 64.84%
Perf 3Y
292.82%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
159.54% -
Gross Margin
93.48%
Volatility
5.17% 5.78%
Perf 5Y
98.81%
Dividend TTM
-
EV/Sales
4.54
EPS Y/Y TTM
58.46%
Oper. Margin
-9.50%
ATR (14)
3.44
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
3.71
Sales Y/Y TTM
128.99%
Profit Margin
-9.02%
RSI (14)
48.37
Dividend Gr. 3/5Y
- -
Current Ratio
3.74
EPS Q/Q
74.59%
SMA20
1.08%
Beta
0.53
Payout
-
Debt/Eq
0.25
Sales Q/Q
106.87%
SMA50
-3.80%
Rel Volume
0.47
Prev Close
64.79
Employees
370
LT Debt/Eq
0.25
SMA200
-6.13%
Avg Volume
630.36K
Price
63.48
IPO
Oct 16, 2020
Option/Short
Yes / Yes
Trades
Volume
293,644
Change
-2.02%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-24-26 Resumed Oppenheimer
Outperform
$105 → $98
Dec-09-25 Initiated Barclays
Overweight
$100
Nov-20-25 Initiated Mizuho
Outperform
$100
Jun-02-25 Resumed Oppenheimer
Outperform
$75
May-27-25 Resumed H.C. Wainwright
Buy
$72
Nov-20-23 Initiated Goldman
Neutral
$19
Jul-18-23 Initiated William Blair
Outperform
$44
May-18-23 Initiated Guggenheim
Buy
Aug-01-22 Initiated Barclays
Overweight
$40
Dec-21-21 Initiated H.C. Wainwright
Buy
$40
Nov-23-21 Initiated Oppenheimer
Outperform
$55
Nov-10-20 Initiated Raymond James
Strong Buy
$39
Nov-10-20 Initiated Ladenburg Thalmann
Buy
$42
Nov-10-20 Initiated Jefferies
Buy
$35
Nov-10-20 Initiated BofA Securities
Buy
$33
Show Previous Ratings
May-14-26 08:30AM
May-07-26 05:00PM
May-06-26 08:37PM
Apr-29-26 04:30PM
Mar-31-26 08:30AM
01:08PM
Loading…
Mar-26-26 01:08PM
(Investor's Business Daily)
Mar-23-26 08:30AM
Mar-06-26 10:22AM
Mar-02-26 01:13PM
(Investor's Business Daily)
Feb-27-26 12:58PM
(Investor's Business Daily)
Feb-26-26 04:30PM
Feb-24-26 12:32PM
12:01AM
Feb-23-26 08:17PM
07:25PM
04:05PM
Loading…
04:05PM
Feb-20-26 07:17AM
Feb-18-26 10:00AM
08:30AM
Feb-17-26 04:30PM
10:00AM
Feb-02-26 12:27PM
Jan-26-26 09:35AM
Jan-13-26 11:40AM
Nov-24-25 04:30PM
Nov-05-25 05:05PM
12:04AM
Nov-04-25 05:55PM
04:05PM
Nov-03-25 07:31AM
05:00PM
Loading…
Oct-28-25 05:00PM
Oct-09-25 09:27AM
Oct-06-25 06:41AM
Aug-27-25 05:00PM
Aug-25-25 06:33PM
Aug-15-25 10:04AM
(Investor's Business Daily)
Aug-14-25 02:48PM
(Investor's Business Daily)
Aug-06-25 06:00PM
04:05PM
Aug-05-25 09:48AM
Jul-30-25 05:00PM
May-29-25 05:00PM
May-14-25 09:45AM
May-08-25 05:00PM
May-05-25 06:04PM
May-02-25 03:17AM
May-01-25 09:37PM
05:35PM
04:05PM
Apr-30-25 10:17AM
09:55AM
Apr-25-25 10:00AM
Apr-24-25 05:00PM
11:00AM
Apr-23-25 01:41PM
Apr-22-25 11:19AM
08:31AM
Apr-21-25 04:05PM
Mar-28-25 03:59PM
Mar-20-25 09:05AM
Mar-12-25 09:49PM
04:12PM
Mar-06-25 05:00PM
Feb-26-25 02:13AM
(Thomson Reuters StreetEvents)
02:05AM
Feb-25-25 08:40AM
07:00AM
01:31AM
Feb-20-25 05:00PM
Jan-30-25 05:00PM
Jan-20-25 03:31PM
Jan-14-25 09:35AM
Jan-13-25 08:30AM
Dec-26-24 10:30AM
(Investor's Business Daily)
Dec-04-24 09:55AM
Nov-18-24 09:55AM
Nov-14-24 02:15AM
Nov-13-24 05:30PM
04:05PM
08:30AM
Nov-07-24 10:00AM
Nov-06-24 04:30PM
Nov-05-24 08:30AM
Oct-30-24 06:39AM
Oct-17-24 08:30AM
Oct-09-24 05:56PM
Sep-25-24 05:00PM
Aug-28-24 05:00PM
Aug-08-24 09:56PM
06:05PM
04:05PM
Jul-29-24 04:30PM
May-29-24 05:00PM
May-09-24 05:00PM
(GlobeNewswire)
-8.86%
+8.70%
12:48PM
11:06AM
03:49AM
May-08-24 08:58PM
05:40PM
04:05PM
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Co-Founder Dr. Bobak R. Azamian M.D.
CFO & Chief Strategy Officer Mr. Jeffrey S. Farrow CPA
Chief Operating Officer Dr. Seshadri Neervannan Ph.D.
M.D. Dr. Bryan Wahl J.D.
Chief Commercial Officer Mr. Aziz Mottiwala M.B.A.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Neervannan Seshadri Chief Operating Officer Mar 20 '26 Sale 66.75 2,989 199,516 82,791 Mar 24 05:05 PM Neervannan Seshadri Officer Mar 20 '26 Proposed Sale 66.75 2,989 199,516 Mar 20 10:38 AM Whitfield Dianne C. Chief Human Resources Officer Mar 18 '26 Sale 68.71 4,071 279,718 39,202 Mar 19 07:04 PM Whitfield Dianne C. Chief Human Resources Officer Mar 17 '26 Sale 69.42 4,029 279,693 43,273 Mar 19 07:04 PM Whitfield Dianne C. Chief Human Resources Officer Mar 19 '26 Sale 67.00 4,174 279,658 35,028 Mar 19 07:04 PM Wahl Bryan General Counsel Mar 17 '26 Sale 69.42 4,084 283,511 72,315 Mar 19 07:04 PM Wahl Bryan General Counsel Mar 19 '26 Sale 67.00 4,231 283,477 63,959 Mar 19 07:04 PM Wahl Bryan General Counsel Mar 18 '26 Sale 68.71 4,125 283,429 68,190 Mar 19 07:04 PM Neervannan Seshadri Chief Operating Officer Mar 19 '26 Sale 67.00 4,589 307,463 85,780 Mar 19 07:04 PM Neervannan Seshadri Chief Operating Officer Mar 18 '26 Sale 68.71 3,610 248,043 90,369 Mar 19 07:04 PM Neervannan Seshadri Chief Operating Officer Mar 17 '26 Sale 69.42 3,125 216,938 93,979 Mar 19 07:04 PM Mottiwala Aziz Chief Commercial Officer Mar 17 '26 Sale 69.42 4,286 297,534 70,250 Mar 19 07:04 PM Mottiwala Aziz Chief Commercial Officer Mar 18 '26 Sale 68.71 4,330 297,514 65,920 Mar 19 07:04 PM Mottiwala Aziz Chief Commercial Officer Mar 19 '26 Sale 67.00 4,440 297,480 61,480 Mar 19 07:04 PM Lin Elizabeth Yeu Chief Medical Officer Mar 19 '26 Sale 67.00 390 26,130 23,308 Mar 19 07:04 PM Lin Elizabeth Yeu Chief Medical Officer Mar 18 '26 Sale 68.71 379 26,041 23,698 Mar 19 07:04 PM Lin Elizabeth Yeu Chief Medical Officer Mar 17 '26 Sale 69.42 375 26,032 24,077 Mar 19 07:04 PM Farrow Jeffrey S See Remarks Mar 18 '26 Sale 68.71 2,133 146,558 45,502 Mar 19 07:03 PM Farrow Jeffrey S See Remarks Mar 17 '26 Sale 69.42 2,111 146,546 47,635 Mar 19 07:03 PM Farrow Jeffrey S See Remarks Mar 19 '26 Sale 67.00 2,186 146,462 43,316 Mar 19 07:03 PM Azamian Bobak R. President/CEO and Board Chair Mar 18 '26 Sale 68.71 11,667 801,640 45,385 Mar 19 07:03 PM Azamian Bobak R. President/CEO and Board Chair Mar 19 '26 Sale 67.00 11,964 801,588 33,421 Mar 19 07:03 PM Azamian Bobak R. President/CEO and Board Chair Mar 17 '26 Sale 69.42 10,972 761,676 57,052 Mar 19 07:03 PM Farrow Jeffrey S Officer Mar 19 '26 Proposed Sale 67.00 2,186 146,459 Mar 19 04:43 PM Mottiwala Aziz Officer Mar 19 '26 Proposed Sale 67.00 4,440 297,475 Mar 19 04:38 PM Azamian Bobak R. Officer Mar 19 '26 Proposed Sale 67.00 11,964 801,574 Mar 19 04:30 PM Whitfield Dianne C. Officer Mar 19 '26 Proposed Sale 67.00 4,174 279,653 Mar 19 04:24 PM Wahl Bryan Officer Mar 19 '26 Proposed Sale 67.00 4,231 283,472 Mar 19 04:23 PM Neervannan Seshadri Officer Mar 19 '26 Proposed Sale 67.00 4,589 307,457 Mar 19 04:15 PM Lin Elizabeth Yeu Officer Mar 19 '26 Proposed Sale 67.00 390 26,130 Mar 19 04:14 PM Whitfield Dianne C. Officer Mar 18 '26 Proposed Sale 68.71 4,071 279,718 Mar 18 04:33 PM Wahl Bryan Officer Mar 18 '26 Proposed Sale 68.71 4,125 283,428 Mar 18 04:18 PM Azamian Bobak R. Officer Mar 18 '26 Proposed Sale 68.71 11,667 801,637 Mar 18 04:17 PM Neervannan Seshadri Officer Mar 18 '26 Proposed Sale 68.71 3,610 248,042 Mar 18 04:17 PM Farrow Jeffrey S Officer Mar 18 '26 Proposed Sale 68.71 2,133 146,558 Mar 18 04:14 PM Mottiwala Aziz Officer Mar 18 '26 Proposed Sale 68.71 4,330 297,513 Mar 18 04:13 PM Lin Elizabeth Yeu Officer Mar 18 '26 Proposed Sale 68.71 379 26,041 Mar 18 04:11 PM LINK WILLIAM J PHD Director Mar 16 '26 Sale 68.79 12,500 859,819 116,332 Mar 18 04:11 PM Azamian Bobak R. Officer Mar 17 '26 Proposed Sale 69.41 10,972 761,618 Mar 17 04:09 PM Neervannan Seshadri Officer Mar 17 '26 Proposed Sale 69.41 3,125 216,921 Mar 17 04:07 PM Farrow Jeffrey S Officer Mar 17 '26 Proposed Sale 69.41 2,111 146,534 Mar 17 04:03 PM Wahl Bryan Officer Mar 17 '26 Proposed Sale 69.41 4,084 283,490 Mar 17 03:59 PM Whitfield Dianne C. Officer Mar 17 '26 Proposed Sale 69.41 4,029 279,672 Mar 17 03:55 PM Lin Elizabeth Yeu Officer Mar 17 '26 Proposed Sale 69.41 375 26,031 Mar 17 03:47 PM Mottiwala Aziz Officer Mar 17 '26 Proposed Sale 69.41 4,286 297,511 Mar 17 03:42 PM WILLIAM J LINK DIRECTOR Mar 16 '26 Proposed Sale 68.78 12,500 859,787 Mar 16 05:39 PM Neervannan Seshadri Chief Operating Officer Mar 04 '26 Sale 76.67 8,366 641,421 70,817 Mar 05 04:03 PM Neervannan Seshadri Officer Mar 04 '26 Proposed Sale 76.67 8,366 641,421 Mar 04 10:56 AM Whitfield Dianne C. Chief Human Resources Officer Jan 02 '26 Sale 80.67 15,565 1,255,684 23,393 Jan 06 04:05 PM Whitfield Dianne C. Officer Jan 02 '26 Proposed Sale 81.38 15,565 1,266,680 Jan 02 11:22 AM Azamian Bobak R. President/CEO and Board Chair Dec 24 '25 Sale 82.51 6,000 495,089 857,991 Dec 30 04:26 PM BOBAK AZAMIAN OFFICER Dec 24 '25 Proposed Sale 82.51 6,000 495,089 Dec 29 12:22 PM Whitfield Dianne C. Chief Human Resources Officer Dec 16 '25 Sale 80.10 7,397 592,500 38,958 Dec 18 04:09 PM LINK WILLIAM J PHD Director Dec 15 '25 Sale 81.43 12,500 1,017,816 128,832 Dec 17 04:07 PM LINK WILLIAM J PHD Director Dec 15 '25 Sale 81.07 10,446 846,862 0 Dec 17 04:07 PM Lin Elizabeth Yeu Chief Medical Officer Dec 16 '25 Sale 79.50 2,078 165,201 21,941 Dec 17 04:07 PM Lin Elizabeth Yeu Officer Dec 16 '25 Proposed Sale 79.50 2,078 165,202 Dec 16 03:12 PM Whitfield Dianne C. Officer Dec 16 '25 Proposed Sale 80.10 7,397 592,500 Dec 16 10:11 AM William Link Director Dec 15 '25 Proposed Sale 81.02 10,446 846,340 Dec 15 04:38 PM WILLIAM J LINK DIRECTOR Dec 15 '25 Proposed Sale 81.42 12,500 1,017,800 Dec 15 04:08 PM Azamian Bobak R. President/CEO and Board Chair Sep 24 '25 Sale 55.37 6,000 332,220 812,106 Sep 26 04:08 PM Bobak Azamian Living Trust Officer Sep 24 '25 Proposed Sale 55.37 6,000 332,208 Sep 24 04:57 PM LINK WILLIAM J PHD Director Sep 08 '25 Sale 57.00 27,116 1,545,612 143,332 Sep 10 05:03 PM LINK WILLIAM J PHD Director Sep 08 '25 Proposed Sale 57.01 27,116 1,546,000 Sep 08 04:19 PM Azamian Bobak R. President/CEO and Board Chair Aug 11 '25 Sale 50.00 6,000 300,000 818,106 Aug 13 04:32 PM Azamian Bobak R. Officer Aug 11 '25 Proposed Sale 50.00 6,000 300,000 Aug 11 12:43 PM Farrow Jeffrey S See Remarks Jun 17 '25 Sale 40.42 13,608 550,035 36,704 Jun 18 04:07 PM Farrow Jeffrey S Officer Jun 17 '25 Proposed Sale 40.42 13,608 550,088 Jun 17 04:14 PM Lin Elizabeth Yeu Chief Medical Officer Jun 16 '25 Sale 41.08 1,006 41,326 7,694 Jun 17 04:07 PM Lin Elizabeth Yeu Officer Jun 16 '25 Proposed Sale 41.07 1,006 41,321 Jun 16 03:07 PM Mottiwala Aziz Chief Commercial Officer Jun 09 '25 Sale 43.76 17,500 765,800 47,557 Jun 11 04:50 PM Mottiwala Aziz Officer Jun 09 '25 Proposed Sale 44.74 17,500 782,950 Jun 09 10:21 AM
